Key points are not available for this paper at this time.
This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.
Share your take
Add a clinician perspective alongside expert commentary.
ASHIDA et al. (Fri,) studied this question.